Accesswire
28 Sept 2026, 12:45 UTC · 1h ago
Verdict
Headline takes no side. We score NNVC +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
NanoViricides began enrolling and dosing patients in its Phase II clinical trial of NV-387 oral gummies for Ebola on or about September 23, 2026.
Newannounced in press release dated September 28, 2026
More positive than 93% of claims this week
NV-387 is currently the only orally administered drug in clinical trials for Ebola, unlike the infusion-based drugs in the PARTNERS trial.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
The trial is structured as a Phase IIA safety and dose run-in followed by a randomized, controlled Phase IIB efficacy evaluation.
Newannounced in press release dated September 28, 2026
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has successfully started patient enrollment and dosing for its Phase II clinical trial of an Ebola treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+0.7%
Price agrees with the score
$1.45 vs $1.44 close before publication (Sep 25) · not market-adjusted
NNVC chart →
